Trial Profile
A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mercaptamine bitartrate (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Pharmacodynamics
- 22 Jan 2014 New trial record
- 13 Jan 2014 Primary endpoint 'Alanine-aminotransferase-levels' has been met.